XML 114 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue from Contracts with Customers - Summary of Disaggregation of Revenues from Contracts with Customers (Details) - EUR (€)
€ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers € 482,325 € 108,589 € 127,575
Goods and Services Transferred at a Point in Time      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 108,840 16,955 22,828
Goods and Services Transferred Over Time      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 373,485 91,634 104,747
Research & Development      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 178,849 84,428 101,837
Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 303,476 24,161 25,738
Pfizer Inc.      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 371,500    
Pfizer Inc. | Research & Development      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 121,597 14,348 7,173
Genentech Inc      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 49,200 64,000 49,500
Genentech Inc | Research & Development      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 49,195 64,026 49,536
Shanghai Fosun Pharmaceutical (Group) Co., Ltd | Research & Development      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 5,074    
Other | Research & Development      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 2,983 6,054 45,128
COVID-19 Vaccine Revenues | Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 270,490    
Sales To Collaboration Partner | Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers [1] 61,460    
Direct Product Sales to BioNTech Customers | Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 20,553    
Share Of Collaboration Partners Gross Profit | Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers 188,477    
Other Sales | Commercial      
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]      
Revenues from contracts with customers € 32,986 € 24,161 € 25,738
[1] Represents sales to collaboration partner of products manufactured by BioNTech.